Lupin Limited completes VISUfarma acquisition, expanding ophthalmology portfolio and European footprint
Written By: Nikita Jha, BPharm
Reviewed By: Pharmacally Editorial Team
Global pharmaceutical company Lupin Limited has completed its acquisition of VISUfarma B.V. from GHO Capital Partners LLP, marking a strategic step in expanding its specialty care portfolio and strengthening its presence across Europe.
The integration of VISUfarma adds more than 60 branded ophthalmology products to Lupin’s portfolio. These products span multiple eye care segments, including dry eye disease, glaucoma, blepharitis, eyelid hygiene, retinal health, and specialty nutraceuticals. The acquisition also brings an established commercial infrastructure across major European markets such as Italy, the United Kingdom, Spain, Germany, and France.
VISUfarma’s regional footprint is supported by a specialized team with experience in ophthalmology, established physician relationships, and strong local market knowledge. This combination is expected to enhance Lupin’s commercial execution and accelerate growth in the European specialty segment.
The acquisition aligns with rising global demand for ophthalmic treatments, driven by an ageing population and the increasing prevalence of diabetes-related eye disorders. By integrating VISUfarma’s portfolio and capabilities, Lupin aims to strengthen its position in delivering targeted eye care solutions.
Vinita Gupta, CEO, Lupin said the acquisition adds a differentiated portfolio of innovative eye health products and an established commercial platform, while also expanding the company’s European presence and supporting the development of its specialty franchise.
Paolo Cioccetti, CEO Italy, VISUfarma highlighted that the partnership combines VISUfarma’s ophthalmology expertise with Lupin’s global capabilities, positioning the combined entity to advance eye care delivery across Europe and other markets.
Headquartered in Mumbai, Lupin operates in more than 100 markets and focuses on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a broad therapeutic presence across areas including respiratory, cardiovascular, diabetes, infectious diseases, gastrointestinal, central nervous system, and women’s health.
Founded in 2016, VISUfarma focuses exclusively on ophthalmology and reported revenue of €53 million in 2025 across multiple European markets and select international regions.
While financial terms were not disclosed by Lupin, the transaction has been reported at an enterprise value of approximately €190 million. Lupin further stated that the acquisition will be financed through existing cash on its balance sheet and is expected to be accretive to its growth and margin profile.
Reference
PR – Lupin Completes Acquisition of VISUfarma, 02 April 2026, https://www.lupin.com/media/press-releases/pr-lupin-completes-acquisition-of-vis-ufarma
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital, 29 September 2025, https://www.lupin.com/media/press-releases/lupin-strengthens-its-global-specialty-ophthalmology-business-with-acquisition-of-visufarma-from-gho-capital
About the Writer
Nikita Jha BPharm is a pharmacy graduate with expertise in clinical research, pharmacovigilance, and medical writing. In her words, she is passionate about translating complex scientific data into clear, accurate healthcare communications that advance drug safety and patient care.
